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Abstract
Background: The efficacy of antipsychotics can be evaluated using the dimensional models of
schizophrenic symptoms. The D2/D3-selective antagonist amisulpride has shown similar efficacy and
tolerability to other atypical antipsychotics. The aim of the present study was to determine the
efficacy of amisulpride on the dimensional model of schizophrenic symptoms and tolerability in latin
schizophrenic patients.
Method: Eighty schizophrenic patients were enrolled and 70 completed a prospective open-label
3-month study with amisulpride. The schizophrenic symptoms, psychosocial functioning and side-
effects were evaluated with standardized scales.
Results:  The patients showed significant improvement in the five dimensions evaluated.
Amisulpride (median final dose 357.1 mg/d) was well-tolerated without treatment-emergent
extrapyramidal side-effects.
Conclusion: Amisulpride showed efficacy on different psychopathological dimensions and was
well tolerated, leading to consider this drug a first line choice for the treatment of schizophrenia.
Background
The treatment of schizophrenia has shown important
improvements since the introduction of new antipsychot-
ics [1]. These drugs, also called atypical or second genera-
tion antipsychotics (SGAs) bring the possibility of a better
quality of life for patients affected with schizophrenia,
because they have been associated with a better efficacy
over negative symptoms, probably less cognitive impair-
ment and lower probability of extrapyramidal symptoms
(EPS) [2], which is one of their main advantages.
The SGAs increase the release of dopamine in the prefron-
tal cortex and the hippocampus [3]. This effect of SGAs is
critical to improve negative symptoms and cognition, and
to decrease the EPS. The principal hypothesis of their
mechanism of action has been attributed to the antago-
nism of 5-HT2A receptors coupled to weaker antagonism
of dopamine D2 receptors [4,5]. Their effect as 5-HT1A
receptor agonist has also been suggested to contribute to
an atypical antipsychotic profile [6].
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Nevertheless, amisulpride represents an important con-
trast on the theory of the 5HT2A receptor antagonism.
Amisulpride, is a benzamide with high affinity for
dopamine D2 and D3 receptors without affinity for serot-
onin, muscarinic or alpha-adrenergic receptors [7]. Ami-
sulpride also shows selectivity for dopamine receptors in
limbic and hippocampal structures, rather than striatal
region [8].
At low doses (100–300 mg/d), amisulpride binds prefer-
entially on D2/D3 presynaptic autoreceptors [8,9], increas-
ing dopaminergic transmission in the prefrontal cortex,
which is believed to be associated with improvement of
primary negative symptoms. Doses between 400–800
mg/d result in antagonism of postsynaptic dopamine
receptors [8], leading to an improvement of positive
symptoms of schizophrenia with less EPS development.
The limbic selectivity of amisulpride is similar to the
observed with clozapine, and is secondary to its high
affinity for D3 receptors and the short isoform of the D2
receptor, which are highly distributed in these regions
[10]. This selectivity has been documented in animal
models [7]. In addition, PET studies have shown that
receptor D2 occupancy in striatal regions is around 14%
when amisulpride is prescribed at doses between 50–100
mg/d [11]. A decreased amisulpride plasma concentration
induces a low percentage of occupancy in striatal and
increased occupancy in limbic regions [12].
The improvement of negative symptoms has been docu-
mented in clinical studies with doses between 50–100
mg/d [13,14]. Until now, amisulpride is the only antipsy-
chotic that has shown scientific evidence of its efficacy
over the primary negative symptoms of schizophrenia
[15-18]. Several clinical trials have shown that amisul-
pride has similar efficacy and better tolerability in com-
parison to haloperidol and flupentixol [19-22] as well as
similar efficacy and safety when compared to olanzapine
and risperidone [23-27]. Additionally, amisulpride has
shown a positive effect over depressive symptoms [28,29]
and the cognitive impairment [30,31] related to
schizophrenia.
These data support that amisulpride is also an 'atypical'
antipsychotic despite having a different receptor-affinity
profile. However, there is a lack of studies about the effi-
cacy and tolerability of amisulpride in latin populations.
We decided to perform a 3-month open trial to determine
these parameters on a sample of Mexican patients, using
the five-factor model of schizophrenic psychopathology, a
previously determined useful strategy for the evaluation
of drug efficacy [32].
Method
Subjects were consecutively recruited from the inpatient
and outpatient services from 7 centers in Mexico between
August 2001 and January 2003. The study was conducted
in accordance with the Good Clinical Practices and the
Declaration of Helsinki. The study protocol was approved
by an Institutional Review Board and Ethics Committee at
each center. Written informed consent was obtained after
the procedures had been fully and detailed explained to
patients.
The sample comprised men and nonpregnant, nonlactat-
ing women aged 18 to 65 years who met diagnostic crite-
ria of schizophrenia (as per DSM-IV), including patients
on their first-episode psychosis (defined as their first psy-
chiatric admission due to psychosis with a maximum
duration of untreated illness of 5 years), patients with
acute psychotic symptoms (defined by baseline PANSS
total score of at least 60 with a minimum score of 4 on at
least 2 items of the positive subscale) due to antipsychotic
treatment noncompliance and patients requiring treat-
ment switch due to lack of efficacy (positive and/or nega-
tive symptom persistence) or presence of adverse events.
Patients were excluded if they had history of bipolar dis-
order, high risk for suicide or agitation/violence, concom-
itant medical or neurological illness (as per review of
systems, and general physical examination) and DSM-IV
defined current substance abuse or a history of substance
dependence in the last six months.
Assessments
Diagnoses were based on the Structured Clinical Interview
for DSM-IV Axis I Disorders (SCID-I) [33] according to
DSM-IV criteria. Efficacy was rated using the dimensional
models of schizophrenic symptoms, based on confirma-
tory 5 factor analysis (positive, negative, cognitive, excite-
ment and depression/anxiety factors) of the Positive and
Negative Syndrome Scale (PANSS) (each item rated from
1 to 7) in Mexican population [34], the Clinical Global
Impression Scale (severity and improvement subscales
rated from 0 to 7) [35] and the Calgary Depression Scale
for Schizophrenia (CDSS) [36] for depressive symptoms.
The efficacy of amisulpride was examined on other
dimensions of schizophrenia, such as psychosocial func-
tioning, with the Psychosocial Aptitude Rating Scale
(PARS) (10 items rated from 0 to 10, where a total score
of "0" denotes the least healthy end of the functioning
range, and "100" the healthiest end) [37]. Tolerability was
assessed with the Barnes Akathisia Scale (BAS) for aka-
thisia [38], the Simpson Angus Scale (SAS) for EPS [39]
and the Abnormal Involuntary Movements Scale (AIMS)
for dyskinesia [40]. For each patient, the same investigator
rated these measures at baseline, day 15, day 30 and day
90.BMC Psychiatry 2005, 5:22 http://www.biomedcentral.com/1471-244X/5/22
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Treatment
This was an open label study using flexible doses (100
mg/d – 1200 mg/d) of amisulpride. Patients with pre-
dominantly negative symptoms, defined as a greater score
on the negative than on the positive subscale in the
PANSS, a negative subscale score >20, at least moderate
global negative symptom score (items score as 4) and
absence of depression [41] received an initial dose of 100
mg/d – 300 mg/d, while patients with predominantly
positive symptoms (defined as a greater score on the pos-
itive than on the negative subscale in the PANSS) [41]
received an initial dose ≥ 400 mg/d. During the 3-month
treatment phase, the drug doses were adjusted based on
clinical considerations, treatment response and side
effects. Patients with lack of clinical response and/or pres-
ence of adverse events with the antipsychotic they were
taking before were switched to amisulpride tapering off
the previous antipsychotic agent and gradually titrating
amisulpride to the established therapeutic dose. Biperi-
den (2–12 mg/d) was prescribed for the treatment of EPS,
lorazepam (0.5–4 mg/d) for anxiety and akathisia, and
antidepressant medication was allowed for the treatment
of depressive symptoms.
Analysis
Demographic and clinical characteristics description was
done with frequencies and percentages for categorical var-
iables and with means and standard deviations (S.D.) for
continuous variables. The effect of treatment was assessed
using repeated measures ANOVA for continuous con-
trasts. Where appropriate, paired t-test (two tailed) were
conducted to examine the differences. For the analysis of
patients with predominantly positive symptoms and pre-
dominantly negative symptoms, changes from baseline to
endpoint in PANSS dimensions and the PARS score were
examined and compared using an analysis of covariance
(ANCOVA) model adjusted for baseline scores. The
improvement criteria a priori specified in the study
required a ≥  20% decrease from baseline in PANSS total
score to study endpoint. However, we also examined the
results with ≥  30% decrease from baseline in PANSS total
score as the criterion for response, as the latter may be
more clinically meaningful. Chi square test (x2) was used
for the comparison of improvement and response criteria
between patients with predominantly positive symptoms
and predominantly negative symptoms. The significance
level for tests was established at p = 0.01 to decrease the
Type 1 error as a consequence of multiple comparisons.
Results
A total of 80 patients were included, their demographic
and clinical characteristics are described in table 1. The 3-
month treatment phase was completed by 70 (87.5%)
patients. The most frequent reason for premature with-
drawal was the lack of clinical response (n = 6). The other
reasons for discontinuation from the study were the lost
to follow-up (n = 3), serious adverse events (severe EPS in
one patient and overdosing in one patient) and non-com-
pliance (n = 1). Non-compliance was determined when
patients discontinued their treatment for a period longer
than 1 week. Only three patients with first-episode were
discontinued from the study. The data from these 70
patients remaining in the study is reported.
The mean initial dose of amisulpride was 335.7 mg/day
(S.D. = 147.4, median 350 mg/day) and the mean dose at
the end of the study was 357.1 mg/day (S.D. = 159.3,
median 400 mg/day). The amisulpride doses were not dif-
ferent between first episode and chronic patients.
Efficacy data
Treatment with amisulpride was associated with a highly
significant improvement on the five factors and on the
total score of the PANSS. The improvement was observed
from the end of the second week with a substantial reduc-
tion in the severity of the symptoms, patients reached a
high level of improvement evaluated with CGI-I and this
level was maintained at the end of third month. The
depressive symptoms evaluated with CDSS were mild to












Switched from previous antipsychotic 48 (60)
Noncompliance 20 (25)
First Episode 12 (15)
Mean (S.D.)
Age 33.1 (10.3)
Age at onset 22.6 (6.7)
Length of illness (yr.) 10.5 (8.2)
PANSS total score 90.9 (23.8)BMC Psychiatry 2005, 5:22 http://www.biomedcentral.com/1471-244X/5/22
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moderate at baseline, the CDSS total score decreased sig-
nificantly through the study (Table 2).
Amisulpride treatment also improved the social function-
ing measured with the PARS (baseline = 47.6, S.D. = 18.6
vs 3-month = 73.9, S.D. = 17.2, t = 10.3, df = 69, p <
0.001) and none was an inpatient at the end of the study.
A higher frequency of patients with predominantly posi-
tive symptoms was found (n = 40, 57%). All negative
symptom subjects were classified as having the undiffer-
entiated subtype of schizophrenia according to DSM-IV
criteria. The mean final doses were 343 mg/day (S.D. =
143.1, median 350 mg/day) for the predominantly
negative group and 392.5 mg/day (S.D. = 183.1, median
400 mg/day) for the predominantly positive subjects.
Amisulpride was associated to similar improvement in all
the five-factors of the PANSS. The mean baseline and
changes from baseline to endpoint in PANSS dimensions
scores for both groups are shown in Table 3. The predom-
inantly positive patients showed a lower psychosocial
functioning at baseline when compared to the
predominantly negative group (t = 3.58, df 68, p = 0.001),
however, no statistically significant differences emerged
between groups at the end of the study (predominantly
negative = 72.5 SD = 20.19; predominantly positive =
75.07 SD = 14.74, t = 0.61, df 68, p = 0.53).
Response rate analysis
The improvement rate in the total sample was 82.9%
using the >20% reduction in PANSS total score while
response rate was 75.7% using the ≥ 30% reduction in
PANSS total score. Similar improvement rates were found
in the predominantly negative patients (73.3%) and in
the predominantly positive patients (90.0%) (x2 = 3.35, df
1, p = 0.07). In the same way, similar response rates were
found in both groups (predominantly negative 66.7% vs.
predominantly positive 82.5%) (x2 = 2.33, df 1, p = 0.12).
Tolerability data
Amisulpride significantly decreased the EPS and abnor-
mal involuntary movements at the end of the study. There
were no significant differences in akathisia's severity dur-
ing the study, although it remained as mild. There was a
trend toward a slight weight increase with the use of ami-
sulpride during the 3-month treatment phase (Table 4).
A total of 10 patients (12.5%) required the use of biperi-
den (4.0 mg/day, S.D. = 3.1) for EPS control at baseline,
only 2 patients (2.8%) continued on anticholinergic
medication (1.5 mg/day, S.D. = 0.70) at the end of the
study. In addition 2 patients (2.5%) required antidepres-
sants (paroxetine and reboxetine, respectively) at the
beginning of the study but none at the end of the study.
Sixteen 16 patients (20%) required lorazepam for anxiety
or insomnia at baseline, but only 3 (4.2%) required this
drug at the end of the study.
Akathisia was the main adverse event reported during the
study (n = 4), followed by headache (n = 1), insomnia (n
= 1) and amenorrhea (n = 1). All side effects were reported
as mild.
Discussion
The factor-analysis studies of the PANSS produced five
factors (positive, negative, cognitive, excitability/hostility
Table 2: Effects of treatment on PANSS factors, depressive symptoms and the clinical global impression.
Baseline Week 2 Week 4 Week 12 Statistics p value
PANSS Factors
Positive 25.7 (8.6) 18.2 (6.6) 14.7 (7.1) 13 (6.6) F(3,77) = 33 <0.001
Negative 26.8 (8.3) 19.3 (7.1) 16.3 (7.3) 13.8 (6.4) F(3,77) = 41.1 <0.001
Cognitive 19.8 (6.2) 14 (5.2) 12.8 (5.2) 11.2 (5) F(3,77) = 24.4 <0.001
Excitement 9.4 (4.1) 6.1 (2.8) 5.6 (3) 5.2 (2) F(3,77) = 17.6 <0.001
Depression/Anxiety 9.7 (4.3) 7.3 (2.9) 6.4 (3) 5.4 (2.6) F(3,77) = 21.6 <0.001
Total Score 91.5 (23.8) 78.4(16.9) 56 (21.9) 48.8 (20.1) F(3,77) = 43.6 <0.001
CDSS 3.9 (4.9) 2.4 (3) 1.7 (2.9) 1 (2.7) F(3,77) = 9.6 <0.001
CGI
Severity 4.7 (1.1) 3.4 (1.1) 2.8 (1.2) 2.3 (1.4) F(3,77) = 54.2 <0.001
Improvement 2.5 (0.9) 2.2 (1) 2.3 (1.4) F(2,78) = 2.1 0.12
Mean (S.D.)
PANSS, Positive and negative syndrome scale
CDSS, Total score of the Calgary depression scale for schizophrenia
CGI, Clinical global impression scaleBMC Psychiatry 2005, 5:22 http://www.biomedcentral.com/1471-244X/5/22
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and depression/anxiety), this solution fits better to the
multidimensional model described for the psychopathol-
ogy of schizophrenia [42-44]. Our results demonstrated a
substantial benefit with amisulpride on the five dimen-
sions of psychopathology based on confirmatory factor
analysis of the PANSS in Mexican schizophrenic patients.
This confirms the properties of amisulpride as an atypical
antipsychotic given its efficacy and low frequency of EPS
showed in this study. The findings of this study resemble
previous reports of the efficacy of amisulpride among the
dimensions obtained from factor analysis of BPRS
[22,28,29].
Amisulpride also improved the psychosocial functioning
of the patients and was associated with discharge from the
hospital in subjects who were initially inpatients. These
two variables could be associated with the drug's efficacy,
better tolerability, or both. It has been observed that atyp-
ical antipsychotics improve the functioning and reduce
the global negative symptoms; amisulpride has shown
Table 3: Mean change from baseline to endpoint in secondary efficacy measures




Statistic* Between Groups Statistic* During the Follow-up
Mean SD Mean SD
Positive
Baseline 19.5 6.8 30.4 6.8 F = 1.09, df 1, p = 0.29 F = 79.58, df 1, p < 0.001
Mean Change -7.2 10.1 -16.7 9.6
Negative
Baseline 30.8 8.6 23.8 6.8 F = 0.16, df 1, p = 0.68 F = 80.18, df 1, p < 0.001
Mean Change -16.3 11.2 -10.5 8.1
Cognitive
Baseline 18.5 6.7 20.7 5.7 F = 0.01, df 1, p = 0.91 F = 111.29, df 1, p < 0.001
Mean Change -7.1 9.4 -9.6 7.3
Excitement
Baseline 8.0 4.0 10.4 3.9 F = 2.63, df 1, p = 0.10 F = 304.76, df 1, p < 0.001
Mean Change -3.1 4.7 -4.9 4.7
Depression-Anxiety
Baseline 8.9 4.2 10.3 4.2 F = 0.16, df 1, p = 0.68 F = 171.77, df 1, p < 0.001
Mean Change -3.6 4.9 -4.7 5.1
Total score
Baseline 85.8 25.1 95.8 22.1 F = 0.05, df 1, p = 0.82 F = 94.80, df 1, p < 0.001
Mean Change -37.4 35.3 -46.6 28.4
* Based on analysis of covariance adjusted for baseline score.
Table 4: Summary of tolerability data during the treatment phase.
Baseline Week 2 Week 4 Week 12 Statistics p value
SAS 4.3 (5.9) 2.2 (4) 2.1 (3.7) 2 (3.7) F (3,77) = 5.1 <0.001
BAS 2.2 (3.2) 1.5 (2.8) 1.3 (2.2) 1.3 (2.2) F (3,77) = 2.2 0.09
AIMS 3.8 (5.9) 2.5 (4.8) 2.1 (3.9) 1.8 (4.1) F (3,77) = 5.0 <0.001
Weight (kg,) 70.7 (13.5) 70.5 (12.9) 70.9 (13.2) 71.4 (13.2) F (3,77) = 2.3 0.08
Mean (S.D.)
SAS, Total score of the Simpson Angus scale
BAS, Total Score of the Barnes akathisia scale
AIMS, Total score of the abnormal involuntary movements scaleBMC Psychiatry 2005, 5:22 http://www.biomedcentral.com/1471-244X/5/22
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similar efficacy to the reported of risperidone [23,26] and
olanzapine [24,27] in the treatment of these symptoms.
Similarly to previous reports, amisulpride improved the
depressive [22,29] and cognitive symptoms [30,31]. This
finding also increase the evidence of the atypical proper-
ties of amisulpride, despite its action as D2/D3 antagonist
without affinity with other neurotransmitter systems.
In the current study, amisulpride produced substantial
and significant reductions in psychopathology during the
follow-up both in patients classified with predominantly
negative or predominantly positive symptoms, without
statistically significant difference between the groups. This
finding could be explained by the dual pharmacodynamic
effect of amisulpride [7-9]. Although both improvement
and clinical response were observed in the groups accord-
ing to predominant symptoms; patients with predomi-
nantly positive symptoms showed a trend to improve in
higher rates.
The mean dose used in this study was lower than the doses
reported in other studies which included patients with
acute exacerbation of positive symptoms (600 mg/day)
[45], given that the present sample included patients with
predominantly negative symptoms, which have been
reported to respond to lower doses of amisulpride. How-
ever, the final doses for patients with predominantly neg-
ative symptoms and predominantly positive symptoms
did not differ, probably because some patients from the
first group showed an increase on the severity of positive
symptoms during the follow up. The most frequently pre-
scribed dose was 400 mg/day for the treatment of patients
with acute symptoms and first episode of psychosis.
Amisulpride was well tolerated, the need for concomitant
medication was reduced at the end of the study and the
reported adverse events were mild. The total weight
increase was 0.7 kg during the 3-month treatment phase.
This increase was similar to the reported in other studies
[46] and lower to the 1.4 kg increase reported in previous
meta-analysis [47]. This finding could be explained by the
fact that in 20 patients (28.6%) a mean 2.1 kg of weight
decrease was registered. Indeed, it has been demonstrated
in randomized 6 months follow-up studies that
amisulpride is associated with less weight gain than risp-
eridone or olanzapine [25,27].
The observed decrease on the abnormal involuntary
movements at the end of the study could also be
explained by the treatment switch. Although only one
patient reported an adverse event associated with hyper-
prolactinemia, this adverse event could not be rejected
since in this study prolactin levels were not regularly
measured. Amisulpride tended to increase prolactin levels
when compared with other atypical antipsychotics
[48,49]. Some studies reported few adverse events related
with hiperprolactinemia [50], this is probably due to the
decrease of prolactin levels with the long term treatment
[51].
The findings of this study were similar to those observed
in other international clinical trials with amisulpride, but
should be considered with caution since one of its limita-
tions was the open label design with a short term follow-
up. Another limitation was that the outpatients outnum-
bered the inpatients, since the high cost of treatment in
Mexico does not permit to afford the inpatient services.
This sample distribution could not allow the results to be
generalized to other countries where subjects with moder-
ate or severe symptoms are treated as inpatients. Further
studies should include adequate instruments for the
assessment of cognitive symptoms as well as laboratory
measures of prolactin, glucose and lipids levels.
Conclusion
The efficacy and tolerability profile of amisulpride in a
Mexican population of schizophrenic patients is similar to
that reported with other second generation antipsychot-
ics, leading to consider this drug as first line for the treat-
ment of schizophrenia.
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